Medicare Begins Covering Obesity Drugs for First Time Starting July 1

Improved access to obesity treatment for Medicare beneficiaries may reduce weight-related health complications and hospitalizations among seniors.

Beginning July 1, 2026, Medicare crosses a threshold it has never crossed before — covering obesity medications for the first time in the program's six-decade history. For millions of seniors managing weight-related illness on fixed incomes, the arrival of GLP-1 drugs like Ozempic and Wegovy under a $50 monthly cap represents not merely a policy update, but a quiet redefinition of what the federal government owes its aging citizens in the realm of health. The shift acknowledges, at last, that obesity is a medical condition rather than a moral failing — and that access to its treatment should n

Medicare Begins Covering Obesity Drugs for First Time Starting July 1

Cobertura Relacionada

Receba o Register no seu e-mail